Leukemias and Lymphomas

Leukemia and lymphomas are some of the most common types of cancer in children, affecting one in three children who are diagnosed with pediatric cancer. These diseases are cancers of white blood cells and immune system, hindering the ability of the body to fight off infections. The cancer cells grow too fast and fill up the bone marrow, crowding out the good blood cells. This leaves the body with fewer healthy white blood cells to fight infections.

These trials focus on combinations of medications, therapies and treatment regimens to help the white blood cells and other parts of the immune system prevent infection and to lessen the time or severity of treatment for children of all ages.

High Risk B-Precursor Acute Lymphoblastic Leukemia

Protocol ID: AALL0232

Disease: ALL

Who can participate?: Patients ≥1 year and < 31 years of age at the time of relapse will be eligible

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Study of JAK1/JAK2 Inhibitor Ruxlitinib with chemotherapy in children with De Novo High Risk CRLF2 rearranaged and/or JAK pathway mutant ALL

Protocol ID: AALL15P1

Disease: ALL

Who can participate?: Patients must be less than 30 years of age at the time of study enrollment

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Protocol ID: AALL1621

Disease: ALL

Who can participate?: Patient must be ≥ 12 months and < 22 years of age at first diagnosis of APL

Lead Researcher: Mark A. Ranalli, MD

Phase 3 trial of Philadelphia chromosome-positive acute lymphoblastic leukemia (PPh+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Protocol ID: AALL1631

Disease: ALL

Who can participate?: Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS)

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Study of MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenille Myelomonocytic Leukemia

Protocol ID: ADVL1521

Disease: ALL

Who can participate?: Diagnosis of ALL at ≥ 1 year and ≤ 21 years of age, in first remission. Enrollment on a COG therapeutic study for ALL is not required

Lead Researcher: Mark A. Ranalli, MD

A Randomized Web Based Physical Activity Intervention among Children's and Adolescents with Acute Lymphoblastic Leukemia

Protocol ID: ALTE1631

Disease: ALL

Who can participate?: Children aged 2 to < 18 years of age

Lead Researcher: Mark A. Ranalli, MD

Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat followed by Fludatabine, Cytarabine, and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refectory AML

Protocol ID: TACL2016-003

Disease: AML

Who can participate?: Age greater than or equal to 3 and less than 22 years at the time of diagnosis

Lead Researcher: Mark A. Ranalli, MD

Rare and Cutaneous Non-Hodgkins Lymphoma Registry

Protocol ID: ANHL04B1

Disease: NHL

Who can participate?: Age 0-20.99 years

Lead Researcher: Mark A. Ranalli, MD

Procurement of Bone Marrow and Peripheral Blood for Patients Potentially Going To Be Enrolled in Leukemia/Lymphoma Research Studies

Protocol ID: Leukemia ONE

Disease: Leukemia, Lymphoma

Who can participate?: Infant to 31 years

Lead Researcher: Robyn M. Dennis, MD

Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Protocol ID: AflacLL1401

Disease: AML

Who can participate?: Patients must be ≥ 1 and ≤ 21 years of age

Lead Researcher: Terri L. Guinipero, MD

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Protocol ID: Amgen (Onyx)

Disease: ALL

Who can participate?: ≤ 21 years at time of initial ALL diagnosis AND > 1 year at time of study treatment initiation.

Lead Researcher: Susan I. Vear, MD

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia

Protocol ID: AALL1521

Disease: ALL

Who can participate?: Age > 1 year and ≤ 21 years at time of leukemia diagnosis

Lead Researcher: Mark A. Ranalli, MD

AAML1421, A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

Protocol ID: AAML1421

Disease: AML

Who can participate?: Patients must be ≥ 1 year and ≤ 21 years of age at the time of enrollment

Lead Researcher: Mark A. Ranalli, MD